Cellectis (CLLS) Change in Working Capital (2015 - 2026)
Cellectis (CLLS) recorded quarterly Change in Working Capital of $611000.0 in Q1 2026, down 99.25% quarter-over-quarter from $81.8 million in Q4 2025, and down 34.09% on a YoY basis from $927000.0 in Q1 2025.
Cellectis (CLLS) Change in Working Capital (2015 - 2026) Analysis & Trends
Cellectis' Change in Working Capital history runs 12 years deep, the most recent figure standing at $611000.0 for Q1 2026.
- In Q1 2026, Change in Working Capital fell 34.09% year-over-year to $611000.0; the TTM figure through Mar 2026 stood at $41.3 million (up 194.14% YoY), while the FY2025 annual figure was $41.6 million, up 177.5% from the prior year.
- Change in Working Capital was $611000.0 for Q1 2026 at Cellectis, down from $81.8 million in the prior quarter.
- In the past five years, Change in Working Capital ranged from a high of $81.8 million in Q4 2025 to a low of -$102.1 million in Q4 2024.
- Historically, Change in Working Capital has averaged -$3.4 million across 5 years, with a median of -$1.6 million in 2023.
- Biggest YoY gain for Change in Working Capital was 18292.31% in 2022; the steepest drop was 18526.83% in 2022.
- A 5-year view of Change in Working Capital shows it stood at $6.2 million in 2022, then tumbled by 725.52% to -$38.7 million in 2023, then sank by 163.91% to -$102.1 million in 2024, then jumped by 180.15% to $81.8 million in 2025, then plunged by 99.25% to $611000.0 in 2026.
- The last three Change in Working Capital figures came in at $611000.0 (Q1 2026), $81.8 million (Q4 2025), and -$37.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Working Capital (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 611,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 611,000.00 |
| Mar 31, 2026 | 611,000.00 |
| Dec 31, 2025 | 81.81 Mn |
| Dec 31, 2025 | 81.81 Mn |
| Sep 30, 2025 | -37.85 Mn |
| Sep 30, 2025 | -37.85 Mn |
| Jun 30, 2025 | -3.30 Mn |
| Jun 30, 2025 | -3.30 Mn |
| Mar 31, 2025 | 927,000.00 |
| Mar 31, 2025 | 927,000.00 |
| Dec 31, 2024 | -102.07 Mn |
| Dec 31, 2024 | -102.07 Mn |
| Sep 30, 2024 | -3.71 Mn |
| Sep 30, 2024 | -3.71 Mn |
| Jun 30, 2024 | 61.01 Mn |
| Jun 30, 2024 | 61.01 Mn |
| Mar 31, 2024 | -8.89 Mn |
| Mar 31, 2024 | -8.89 Mn |
| Dec 31, 2023 | -38.68 Mn |
| Dec 31, 2023 | -38.68 Mn |